C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.380
-0.030 (-0.88%)
At close: Sep 17, 2025, 4:00 PM EDT
3.370
-0.010 (-0.30%)
After-hours: Sep 17, 2025, 7:56 PM EDT
C4 Therapeutics Employees
C4 Therapeutics had 110 employees as of December 31, 2024. The number of employees decreased by 35 or -24.14% compared to the previous year.
Employees
110
Change (1Y)
-35
Growth (1Y)
-24.14%
Revenue / Employee
$311,273
Profits / Employee
-$1,014,373
Market Cap
240.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | 99 | 11 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CCCC News
- 13 days ago - C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewsWire
- 14 days ago - C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 5 weeks ago - C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - C4 Therapeutics: An Entry Point If There's Ever Going To Be One - Seeking Alpha
- 4 months ago - C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 months ago - C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 months ago - C4 Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 10 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire